FIELD: medicine.
SUBSTANCE: present invention refers to immunology. Presented are an antibody and its antigen-binding fragment able to bind to human delta-like ligands 4 (DLL4), including in the form of a labelled antibody or its antigen-binding fragment, a structure with a constant domain of immunoglobulin, a conjugate with a therapeutic or cytotoxic agent and in the crystallised form. Besides, disclosed are: an isolated nucleic acid coding the antibody or its fragment according to the invention, an expression vector, a host cell and a method for producing the antibody or its antigen-binding fragment; as well as a pharmaceutical composition for modulating a disease or a disorder, a method for reducing human DLL4 activity and a method of treating a patient suffering a disorder associated with the negative effect of DLL4.
EFFECT: antibody according to the present invention or its antigen-binding fragment have an ability to block Notch1 signalling that can find further application in a therapy of the diseases mediated by Notch1 signal pathway overactivity.
49 cl, 31 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| IL-12/P40 BINDING PROTEINS | 2006 |
|
RU2461571C2 |
| ANTI-VEGF ANTIBODIES AND APPLICATIONS THEREOF | 2010 |
|
RU2567639C2 |
| ANTIBODIES SPECIFIC FOR LIGAND 1A, SIMILAR TO TUMOR NECROSIS FACTOR, AND THEIR COMPOSITIONS AND APPLICATION | 2014 |
|
RU2708140C1 |
| HIV ANTIBODY COMPOSITIONS AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2757135C2 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
| DLL4 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415869C2 |
| ANTIBODIES TO JAGGED AND METHODS OF THEIR USE | 2013 |
|
RU2666990C2 |
| HUMANISED ANTIBODIES AGAINST HUMAN ALPHA INTERFERON | 2009 |
|
RU2532832C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
